Results 141 to 150 of about 118,448 (336)

The Persistence of Dopamine Dysregulation Syndrome after Pallidal Deep Brain Stimulation in Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Dopamine dysregulation syndrome (DDS) is a debilitating complication of Parkinson's disease (PD) dopamine replacement therapy (DRT) in which patients pathologically and/or compulsively use dopaminergic drugs to treat motor symptoms. Studies examining DDS outcomes following deep brain stimulation (DBS) are limited and have focused on
Natalie David, Stewart A. Factor, Richa Tripathi, Lenora Higginbotham   +3 more
wiley   +1 more source

A pseudopeptide that is a potent cholecystokinin agonist in the peripheral system is able to inhibit the dopamine-like effects of cholecystokinin in the striatum.

, 1988
Christiane Mendre, Meghan Rodriquez, Christiane Gueudet, MARIE‐FRANÇOISE LIGNON, Marie‐Christine Galas, Jeanine Laur, P. Worms, Jean Martínez   +7 more
openalex   +1 more source

Lack of Discrimination by Agonists for D2 and D3 Dopamine Receptors [PDF]

, 1995
Kevin D. Burris, Mary A. Pacheco, Theresa M. Filtz, Mei‐Ping Kung, Hank F. Kung, Perry B. Molinoff   +5 more
openalex   +1 more source

Health‐Related Quality of Life in Relation to the 5‐2‐1 Criteria in Parkinson's Disease in Sweden

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Device‐aided therapies (DAT) offer alternatives to oral or transdermal dopaminergic treatments in advanced Parkinson's disease (PD), where they can reduce motor fluctuations and dyskinesia and improve health‐related quality of life (HRQoL).
Frida Hjalte, Anna Gustafsson, Jenny Samuelsson, Filip Bergquist, Anders Johansson, Per Odin   +5 more
wiley   +1 more source

Chronic exposure to dopamine agonists affects the integrity of striatal D2 receptors in Parkinson's patients

NeuroImage: Clinical, 2017
We aimed to investigate the integrity and clinical relevance of striatal dopamine receptor type-2 (D2R) availability in Parkinson's disease (PD) patients. We studied 68 PD patients, spanning from early to advanced disease stages, and 12 healthy controls.
Marios Politis, Heather Wilson, Kit Wu, David J. Brooks, Paola Piccini   +4 more
doaj  

Dopamine Agonist-Resistant Microprolactinoma-Mechanisms, Predictors and Management: A Case Report and Literature Review. [PDF]

J Clin Med, 2022
Szmygin H, Szydełko J, Matyjaszek-Matuszek B.   +2 more
europepmc   +1 more source

Biotransformation of l‐DOPA to Dopamine in the Substantia Nigra of Freely Moving Rats: Effect of Dopamine Receptor Agonists and Antagonists [PDF]

, 1998
Sophie Sarre, Diederik Vandeneede, Guy Ebinger, Yvette Michotte   +3 more
openalex   +1 more source

Dopamine D4 receptor counteracts morphine-induced changes in M opioid receptor signaling in the striosomes of the rat caudate putamen. [PDF]

, 2015
Morphine is one of the most potent analgesic drugs used to relieve moderate to severe pain. After long-term use of morphine, neuroadaptive changes in the brain promotes tolerance, which result in a reduced sensitivity to most of its effects with ...
De-la-Calle-Martin, Adelaida, Medina-Luque, José, Rivera-Ramirez, Alicia, Roales-Buján, Ruth, Shumilov, Kirill, Suárez-Boomgaard, Diana, Valderrama-Carvajal, Alejandra   +6 more
core  

Cognitive and Psychiatric Adverse Effects of Foslevodopa/Foscarbidopa in Patients with Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Sacha Brohée, Emmanuel Roze, David Grabli, Hélène Letrillart, Lise Mantisi, Cendrine Foucard, Elodie Hainque, Florence Cormier, Aurélie Méneret, Fabien Hauw   +9 more
wiley   +1 more source

No Dopamine Agonist Modulation of Brain [¹⁸F]FEOBV Binding in Parkinson's Disease. [PDF]

Mol Pharm, 2022
Albin RL, Kanel P, van Laar T, van der Zee S, Roytman S, Koeppe RA, Scott PJH, Bohnen NI.   +7 more
europepmc   +1 more source